Equities
Health CareMedical Equipment and Services
  • Price (EUR)1.24
  • Today's Change0.01 / 0.81%
  • Shares traded4.18k
  • 1 Year change+12.73%
  • Beta-0.2370
Data delayed at least 15 minutes, as of May 31 2024 16:36 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

aap Implantate AG is a Germany-based provider of medical devices for human muscular and skeletal systems. The Company focuses on trauma and biomaterials products for orthopedics. The Biomaterials portfolio comprises bone substitutes for the filling of aseptic bone defects, bone cements and accessories for the application in arthroplasty, bone cements and accessories for the application in vertebroplasty and kyphoplasty. The trauma portfolio includes a wide range of cannulated screws, standard plates and screws for miniature, small and large bone fragments, among others . It also develops LOQTEQ, a technology that allows for fracture compression with subsequent locking fixation in one surgical step. The Company operates a network of distributors in more than 60 countries, and cooperates directly with physicians and hospital customers.

  • Revenue in EUR (TTM)--
  • Net income in EUR--
  • Incorporated1997
  • Employees111.00
  • Location
    Aap Implantate AGLorenzweg 5BERLIN 12099GermanyDEU
  • Phone+49 30750190
  • Fax+49 3 075019111
  • Websitehttps://www.aap.de/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Observe Medical ASA2.46m-5.30m8.38m12.00--0.8247--3.41-1.05-1.050.48490.60630.11912.497.122,328,500.00-25.72-32.60-35.90-49.8033.2432.83-216.03-256.250.334-6.010.3204--43.14204.81-18.82--32.69--
Rua Life Sciences PLC2.20m-2.20m8.75m40.00--0.713--3.98-0.0843-0.08430.08430.16830.32933.264.8046,725.00-32.95-25.97-36.33-28.2681.97---100.05-110.532.40-61.710.1065--34.0940.083.10--94.82--
ScandiDos AB5.70m-424.96k8.99m34.00--2.37--1.58-0.1063-0.10631.430.75880.95730.47877.39---7.14-13.82-13.39-23.9582.5482.49-7.45-17.090.4511-2.630.00--6.704.01-24.27--4.18--
Nanexa AB2.53m-6.19m11.20m19.00--1.37--4.42-0.8143-0.81430.32520.68540.2069-33.452.261,521,474.00-50.54-40.77-66.82-48.77124.7077.27-244.28-532.262.14--0.0193--925.42147.00-30.44--39.10--
Ortivus AB6.85m-1.81m11.27m42.00--8.08--1.65-0.4655-0.46551.760.35291.003.364.761,953,650.00-26.44-2.41-51.70-4.6333.8842.46-26.39-1.770.5256--0.4544---19.5510.00-409.66--67.43--
Medinice SA52.68k-1.19m11.30m16.00--1.50--214.53-0.8125-0.81250.03615.130.0057--0.339914,062.50-12.78-12.47-13.14-12.9633.3362.64-2,254.22-1,404.30----0.015---10.71189.32-4.41--177.91--
Spineguard SA4.31m-4.18m12.13m24.00--2.01--2.81-0.1084-0.10840.11180.12700.38271.284.68179,700.00-37.12-23.69-52.43-42.7372.8975.60-97.00-45.021.73-13.510.3384---22.98-10.65-74.81--89.42--
Neola Medical AB0.00-792.11k12.23m7.00--1.82-----0.1536-0.15360.001.090.00----0.00-11.63-17.04-12.52-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
aap Implantate AG-100.00bn-100.00bn12.23m111.00--0.7827----------1.58-----------28.07---34.07--90.66---74.070.9396--0.1584---5.341.10-1.67---25.10--
Dignitana AB7.51m-1.62m12.67m28.00--46.71--1.69-0.2487-0.24871.150.03841.663.3514.613,175,519.00-35.81-42.21-97.80-68.9169.1166.09-21.55-57.290.3234-8.840.8571--17.9020.5922.52---15.31--
Laboratoires Euromedis SA49.54m-5.51m12.94m194.00--0.4638--0.2611-1.84-1.8416.469.700.82833.544.88255,371.10-9.19---11.45--32.67---11.09--3.57-12.830.2875---51.58---362.99------
Medicon Hellas SA19.86m2.06m12.95m98.006.300.763.360.65190.46520.46524.493.860.6111.882.16--6.736.488.018.1572.1474.4411.0211.21--11.500.3853---3.4110.33-16.688.0824.76--
BibbInstruments AB0.00-960.92k13.48m----4.93-----0.4379-0.43790.001.180.00-------32.19-39.57-34.83-42.71--59.36---8,032.40----0.00------2.72---1.94--
Implanet SA7.45m-6.68m13.62m41.00------1.83-0.1704-0.17040.1933-0.00420.59310.90834.19182,973.00-53.17-37.44-159.90-86.7456.8359.59-89.65-67.430.2932-24.761.03---7.242.08-88.59---2.20--
Ivision Tech SpA9.37m53.62k13.88m146.00258.732.128.471.480.00770.00771.350.9418------64,151.30--------57.67--0.5725--1.222.380.4058--18.59---81.01------
Inspiration Healthcare Group PLC48.28m-646.34k14.03m210.00--0.3397.100.2907-0.0081-0.00810.6030.51630.78792.324.76195,619.00-1.056.14-1.257.6045.5947.42-1.346.001.50-0.12890.2317--0.445821.62-93.58-25.9752.54--
Data as of May 31 2024. Currency figures normalised to Aap Implantate AG's reporting currency: Euro EUR

Institutional shareholders

9.20%Per cent of shares held by top holders
HolderShares% Held
Discover Capital GmbHas of 30 Jun 2023895.49k9.08%
Gutmann Finanz Strategien AGas of 31 Mar 202412.02k0.12%
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.